Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Clin Neuropharmacol ; 25(4): 230-3, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12151911

RESUMO

We investigated whether a combination of risk factors affects the free phenytoin (PHT) fraction by multiple regression analyses in 30 patients with severe motor and intellectual disabilities (SMID) with epilepsy. The risk factors analyzed were gender, age, total PHT concentration, albumin concentration, aspartate aminotransferase, alanin aminotransferase, serum creatinine, blood urea nitrogen, and antiepileptic drug concentrations. Serum levels of total and free PHT were measured by fluorescence polarization immunoassay. Free PHT fractions were between 7.2% and 17.3% (average 10.9%). Two factors, hypoalbuminemia and valproate (VPA) coadministratation with PHT, increased free PHT fraction, and a combination of these two markedly increased free PHT fraction. Patients with these double risk factors have a high risk of exceeding the therapeutic range of serum-free PHT concentration even if their total PHT concentration does not. Therefore, we should monitor free PHT concentration, especially in SMID patients with epilepsy, because they may have hypoalbuminemia and are treated with antiepileptic drug polytherapy and, moreover, cannot report adverse effects of the drugs.


Assuntos
Deficiência Intelectual/sangue , Transtornos das Habilidades Motoras/sangue , Fenitoína/metabolismo , Albumina Sérica/deficiência , Ácido Valproico/sangue , Adolescente , Adulto , Sinergismo Farmacológico , Quimioterapia Combinada , Epilepsia/sangue , Epilepsia/tratamento farmacológico , Feminino , Humanos , Deficiência Intelectual/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Transtornos das Habilidades Motoras/tratamento farmacológico , Fenitoína/sangue , Fenitoína/uso terapêutico , Análise de Regressão , Fatores de Risco , Ácido Valproico/uso terapêutico
2.
J Electrocardiol ; 38(2): 148-51, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15892025

RESUMO

QT prolongation induced by antipsychotics has been reported to be a determinant for the development of torsade de pointes and sudden death. However, the effect of lithium on QT interval has not been fully clarified. The aim of the present study was to elucidate the relationship between serum lithium concentration and QT interval in patients treated with lithium. We examined serum lithium concentrations and electrocardiographic features in 39 inpatients with bipolar affective disorder or schizophrenia. The longest QT interval in the 12 electrocardiographic leads was measured using GE Marquette QT guard System Software, and Bazett formula was used for heart rate correction. The longest QTc was positively correlated with lithium concentration ( r = 0.46, P = .003). Multiple regression analysis revealed that sex (female, P = .037), lower serum K + concentration ( P = .029), and especially, higher serum lithium concentration ( P = .009) were determinants for the prolongation of the QTc.


Assuntos
Eletrocardiografia/efeitos dos fármacos , Lítio/sangue , Transtornos Psicóticos/tratamento farmacológico , Feminino , Humanos , Lítio/uso terapêutico , Masculino , Pessoa de Meia-Idade , Análise de Regressão , Esquizofrenia/sangue , Esquizofrenia/tratamento farmacológico , Fatores Sexuais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA